Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study

References

• Collaborators GBDCRDSorianoJBAbajobirAAGlobal, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015Lancet Respir Med20175969170628822787
   PubMed Web of Science ®Google Scholar
• KewKMDiasSCatesCJLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisCochrane Database of Systematic Reviews20143CD010844
   PubMed Web of Science ®Google Scholar
• HutchinsonABrandCIrvingLRobertsCThompsonPCampbellDAcute care costs of patients admitted for management of chronic obstructive pulmonary disease exacerbations: contribution of disease severity, infection and chronic heart failureIntern Med J201040536437120180870
   PubMed Web of Science ®Google Scholar
• BarjaktarevicIZArredondoAFCooperCBPositioning new pharmacotherapies for COPDInternational Journal of Chronic Obstructive Pulmonary Disease2015101427144226244017
   PubMed Web of Science ®Google Scholar
• GuarascioAJRaySMFinchCKSelfTHThe clinical and economic burden of chronic obstructive pulmonary disease in the USAClinico-Economics and Outcomes Research: CEOR20135235245
   PubMedGoogle Scholar
• WedzichaJASeemungalTACOPD exacerbations: defining their cause and preventionLancet (London, England)20073709589786796
   PubMed Web of Science ®Google Scholar
• SeemungalTADonaldsonGCPaulEABestallJCJeffriesDJWedzichaJAEffect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981575 Pt 1141814229603117
   PubMed Web of Science ®Google Scholar
• GOLDGlobal Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic pulmonary disease2017 Available from: https://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/Accessed November 05, 2018
   Google Scholar
• StynesGSvedsaterHWexJOnce-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD – mixed treatment comparisons of clinical efficacyRespiratory Research2015162525849223
   PubMed Web of Science ®Google Scholar
• DransfieldMTBourbeauJJonesPWOnce-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trialsLancet Respir Med20131321022324429127
   PubMed Web of Science ®Google Scholar
• KosoglouTHubbellJXuanFComparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis2013810711623525511
   PubMed Web of Science ®Google Scholar
• CazzolaMMateraMGNovel long-acting bronchodilators for COPD and asthmaBr J Pharmacol2008155329129918604231
   PubMed Web of Science ®Google Scholar
• VaidyaSSKhindriSCalderNPharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjectsPulm Pharmacol Ther201637303626845343
   PubMed Web of Science ®Google Scholar
• TanRACorrenJMometasone furoate in the management of asthma: a reviewTher Clin Risk Manag2008461201120819337427
   PubMedGoogle Scholar
• CrimCPierreLNDaley-YatesPTA review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoateClinical Therapeutics20012391339135411589253
   PubMed Web of Science ®Google Scholar
• CalverleyPMRennardSNelsonHSOne-year treatment with mometasone furoate in chronic obstructive pulmonary diseaseRespiratory Research200897319014549
   PubMed Web of Science ®Google Scholar
• CazzolaMBardaroFStirpeEThe role of indacaterol for chronic obstructive pulmonary disease (COPD)J Thorac Dis20135455956623991316
   PubMed Web of Science ®Google Scholar
• BattramCCharltonSJCuenoudBIn vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-o ne (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of actionJ Pharmacol Exp Ther2006317276277016434564
   PubMed Web of Science ®Google Scholar
• SlackRJBarrettVJMorrisonVSIn vitro pharmacological characterization of vilanterol, a novel long-acting beta2-adrenoceptor agonist with 24-hour duration of actionJ Pharmacol Exp Ther2013344121823023131596
   PubMed Web of Science ®Google Scholar
• BalintBWatzHAmosCOwenRHigginsMKramerBOnset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasoneInt J Chron Obstruct Pulmon Dis2010531131820856830
   PubMedGoogle Scholar
• CazzolaMProiettoAMateraMGIndacaterol for chronic obstructive pulmonary disease (COPD)Drugs Today (Barc)201046313915020467588
   PubMed Web of Science ®Google Scholar
• GOLDGlobal Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic pulmonary disease2011 Available from: www.goldcopd.orgAccessed November 14, 2018
   Google Scholar
• HankinsonJLOdencrantzJRFedanKBSpirometric reference values from a sample of the general U.S. populationAm J Respir Crit Care Med199915911791879872837
   PubMed Web of Science ®Google Scholar
• MillerMRHankinsonJBrusascoVStandardisation of spirometryEuropean Respiratory Journal200526231933816055882
   PubMed Web of Science ®Google Scholar
• MahlerDAWeinbergDHWellsCKFeinsteinARThe measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexesChest19848567517586723384
   PubMed Web of Science ®Google Scholar
• JonesPWQuirkFHBaveystockCMLittlejohnsPA self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory QuestionnaireAmerican Review of Respiratory Disease19921456132113271595997
   PubMed Web of Science ®Google Scholar
• JonesPWHardingGBerryPWiklundIChenWHKline LeidyNDevelopment and first validation of the COPD Assessment TestEuropean Respiratory Journal200934364865419720809
   PubMed Web of Science ®Google Scholar
• MahlerDAWitekTJJrThe MCID of the transition dyspnea index is a total score of one unitCOPD2005219910317136969
   PubMedGoogle Scholar
• JonesPWSt. George’s respiratory questionnaire: MCIDCOPD200521757917136966
   PubMedGoogle Scholar
• DahlRChungKFBuhlREfficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPDThorax201065647347920522841
   PubMed Web of Science ®Google Scholar
• KornSKerwinEAtisSIndacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week studyRespir Med2011105571972621367594
   PubMed Web of Science ®Google Scholar
• KornmannODahlRCentanniSOnce-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparisonEur Respir J201137227327920693243
   PubMed Web of Science ®Google Scholar
• GOLDGlobal Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic pulmonary disease2014 Available from: www.goldcopd.orgAccessed November 12, 2018
   Google Scholar
• DecramerMLChapmanKRDahlROnce-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group studyLancet Respir Med20131752453324461613
   PubMed Web of Science ®Google Scholar
• TashkinDPDohertyDEKerwinEEfficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trialsInt J Chron Obstruct Pulmon Dis20127738622334770
   PubMed Web of Science ®Google Scholar
• CelliBRBarnesPJExacerbations of chronic obstructive pulmonary diseaseEur Respir J20072961224123817540785
   PubMed Web of Science ®Google Scholar
• RossiAvan der MolenTdel OlmoRINSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPDEur Respir J20144461548155625359348
   PubMed Web of Science ®Google Scholar
• NanniniLJLassersonTJPoolePCombined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20129CD006829
   PubMed Web of Science ®Google Scholar
• NanniniLJPoolePMilanSJHolmesRNormansellRCombined corticosteroid and long-acting beta(2)-agonist in one inhaler versus placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev201311CD003794
   PubMed Web of Science ®Google Scholar